Abstract
Oncology is entering a new era in which patients are being categorized not only by the tissue of origin of their cancer, but also by the molecular characteristics of their tumor. Historically, melanomas have been classified as cutaneous (including superficial spreading, nodular, lentigo maligna, and acral lentiginous subtypes), mucosal, or uveal. Recent molecular analyses have demonstrated that the majority of melanomas harbor one or more genetic alterations in components of key signaling networks. This information is now being integrated with the traditional clinicopathological criteria to develop a more refined system that has both diagnostic and therapeutic implications.
Original language | English (US) |
---|---|
Title of host publication | Targeted Therapeutics in Melanoma |
Publisher | Springer New York |
Pages | 3-15 |
Number of pages | 13 |
ISBN (Electronic) | 9781617794070 |
ISBN (Print) | 9781617794063 |
DOIs | |
State | Published - Jan 1 2012 |
Keywords
- AKT
- Acral lentiginous melanoma
- Amplification
- BRAF
- Comparative genome hybridization
- GNA11
- GNAQ
- Imatinib
- KIT
- MAPK
- MEK
- Mucosal melanoma
- Mutation
- NRAS
- Nevi
- Nodular melanoma
- Oncogene addiction
- PI3K
- PLX4032
- PTEN
- Superficial spreading melanoma
- Targeted therapy
- Uveal melanoma
ASJC Scopus subject areas
- General Medicine